Impact of breast cancer on anti-mullerian hormone levels in young women

H. Irene Su(Union Hospital), Anne Z. Steiner(Children's Hospital of Los Angeles), Angela DeMichele(University of Pennsylvania), Loki Natarajan(University of California System), Shirley W. Flatt(University of California San Diego)

Breast Cancer Research and Treatment

December 8, 2012

10.1007/s10549-012-2361-5

Cited by 52

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer

|Cell|2017|448

Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations

|JNCI Journal of the National Cancer Institute|2006|344

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

|The Lancet Oncology|2021|255